Allopurinol Use in Gout: Cardiovascular Risks and Protective Role of Colchicine
Overview
This editorial discusses a Dutch nationwide study evaluating the time- and dose-dependent cardiovascular risks associated with allopurinol use in gout patients. The study found an increased risk of ischaemic cardiovascular events shortly after allopurinol initiation, especially at doses above 300 mg, which was mitigated by concomitant colchicine therapy.
Background
Gout patients have an elevated risk of cardiovascular morbidity and mortality, partly due to hyperuricaemia-induced oxidative stress and endothelial dysfunction. Urate-lowering therapies (ULT), such as allopurinol, have been investigated for cardiovascular benefits, but evidence remains conflicting. The ALL-HEART trial showed no cardiovascular benefit of allopurinol in patients with ischaemic heart disease without gout, while meta-analyses suggested potential benefits at lower doses. The role of colchicine, an anti-inflammatory agent, has also been explored for cardiovascular event reduction.
Data Highlights
Time Period
Incidence Rate Ratio (IRR)
95% Confidence Interval (CI)
First 30 days after allopurinol initiation
1.51
1.29–1.77
First 30 days, starting dose >300 mg
3.92
2.73–5.63
First 30 days, starting dose <300 mg
1.69
1.31–2.18
First 30 days with colchicine, low-dose allopurinol
1.02
0.78–1.32
First 30 days with colchicine, high-dose allopurinol
1.18
0.65–2.16
Prolonged allopurinol use
1.07
1.03–1.12
30 days after discontinuation
1.20
1.02–1.43
Key Findings
Ischaemic cardiovascular event risk peaks during the first 30 days after starting allopurinol (IRR 1.51).
Higher starting doses (>300 mg) are associated with a markedly increased early cardiovascular risk (IRR 3.92) compared to lower doses (IRR 1.69).
Concomitant colchicine use abolishes the early increased cardiovascular risk associated with allopurinol initiation.
A modestly elevated cardiovascular risk persists during prolonged allopurinol use and shortly after discontinuation.
The study used antiplatelet therapy prescriptions as a proxy for clinically diagnosed ischaemic cardiovascular events in a large nationwide gout cohort.
Clinical Implications
Clinicians should be cautious when initiating allopurinol, particularly at doses above 300 mg, due to transiently increased cardiovascular risk. Co-prescription of low-dose colchicine may mitigate this early risk and should be considered during ULT initiation in gout patients. Monitoring for cardiovascular events is advisable during the early treatment phase and after discontinuation.
Conclusion
Allopurinol initiation in gout patients is associated with a transient increase in ischaemic cardiovascular risk, especially at higher doses, which can be substantially reduced by concomitant colchicine therapy. These findings highlight the dynamic interplay between gout treatment and cardiovascular risk management.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
